Kelley Shannon T. - 18 Aug 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
General Counsel
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol
MDGL
Transactions as of
18 Aug 2025
Net transactions value
-$479,627
Form type
4
Filing time
18 Aug 2025, 17:33:51 UTC
Previous filing
07 Mar 2025
Next filing
20 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kelley Shannon T General Counsel C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN /s/ Mardi Dier, as Attorney-in-Fact 18 Aug 2025 0002034056

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Sale $164,266 -458 -4.4% $358.66 10,019 18 Aug 2025 Direct F1
transaction MDGL Common Stock Sale $46,575 -126 -1.3% $369.64 9,893 18 Aug 2025 Direct F2, F3
transaction MDGL Common Stock Sale $31,085 -84 -0.85% $370.06 9,809 18 Aug 2025 Direct F2
transaction MDGL Common Stock Sale $31,193 -84 -0.86% $371.35 9,725 18 Aug 2025 Direct F2, F4
transaction MDGL Common Stock Sale $93,855 -252 -2.6% $372.44 9,473 18 Aug 2025 Direct F2, F5
transaction MDGL Common Stock Sale $25,441 -68 -0.72% $374.13 9,405 18 Aug 2025 Direct F2, F6
transaction MDGL Common Stock Sale $71,393 -190 -2% $375.75 9,215 18 Aug 2025 Direct F2, F7
transaction MDGL Common Stock Sale $15,818 -42 -0.46% $376.62 9,173 18 Aug 2025 Direct F2, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
F2 This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $369.02 to $369.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $371.22 to $371.48, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $372.25 to $372.76, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $373.77 to $374.36, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $375.46 to $376.06, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $376.60 to $376.64, inclusive.